Cancer Advance Boston provides a cohesive two-day agenda that includes an educational mix of emerging science and clinical breakthroughs, along with partnership and policy discussions, - Steve Tregay, Founder and CEO of FORMA Therapeutics.
Boston, MA (PRWEB) March 19, 2015
Panels will discuss compassionate use, immunotherapy (including T cell therapy), combination therapy, building successful partnerships, biomarkers and more. Panelists include Rafael Amado (Adaptimmune), Lew Cantley (Meyer Cancer Center at Weill Cornell), George Demetri (Dana Farber Cancer Institute), JC Gutierrez-Ramos (Pfizer), Tyler Jacks (MIT Koch Institute), Patrick Mahaffy (Clovis Oncology), Michael Pellini (Foundation Medicine), Michael Rosenblatt (Merck), Phil Sharp (MIT), Markus Warmuth (H3 Biomedicine) and Richard Wooster (Blend Therapeutics), among others. Leading investors from Bain Capital, Wellington Management Company, Pioneer Investments, Deerfield Partners, Fidelity Investments, Sofinnova Ventures, and Third Rock Ventures will also be in attendance.
“Cancer Advance Boston provides a cohesive two-day agenda that includes an educational mix of emerging science and clinical breakthroughs, along with partnership and policy discussions,” said Steve Tregay, Founder and CEO of FORMA Therapeutics. “It has become a ‘go-to’ venue for keeping abreast of the rapidly changing oncology landscape.”
“The convergence of high-quality people—the decision-makers in our industry—in a relaxed, off-the-record environment makes this conference unique,” noted JC Gutierrez-Ramos, Senior Vice President of R&D and Biotherapeutics of Pfizer. "We get to brainstorm in an intimate setting, and the panel discussions are as candid as they are enlightening. We talk about that’s exciting in oncology, but we also challenge each other with tough questions. During networking breaks, you feel the energy in the room: people are connecting and deals are being born. My team and I are proud supporters of this conference because they truly help advance the pace of innovation.”
To view the agenda and for more information, please visit:
ABOUT THE BOSTON BIOTECH CONFERENCES (BBC)
The Boston Biotech Conferences (BBC)’s mission is to build a vibrant community of bio-pharma leaders, which will help to drive innovation in biotech, and bring important drugs to patients more quickly. The conferences are exclusive, thought-leader forums for senior bio-pharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking and corporate development within the bio-pharma community. The meetings are invitation-only, off-the-record forums that bring together the past, present and future leaders in the healthcare community to network, exchange ideas and share insights into the industry's challenges and opportunities. For more information or to register, visit http://www.bbbiotechconference.com.